Navigation Links
ICBS acquires 30% interest in Bacteria Bank Ltd.
Date:10/30/2007

NEW YORK and MONTREAL, Oct. 30 /PRNewswire-FirstCall/ - ICBS Limited (PINKSHEETS: ICBM), today announced the acquisition of 30% interest in Bacteria Bank Ltd.

Bacteria Bank Ltd., is a Bio medical company that owns over ten thousand cryogenically stored bacteria for use in medical research, located in Montreal Canada. The company is headed by Dr. Karl Weiss a world renowned bacteriologist.

Dr. Karl Weiss is a Microbiologist and Infectious Diseases Specialist at Maisonneuve-Rosemont Hospital in Montreal . He is also Associate Clinical Professor at the Faculty of Medicine at University of Montreal , and the director of pharmacological research at Maisonneuve-Rosemont hospital. He is also an associate member of the division of infectious diseases at the Jewish General Hospital in Montreal , and an adjunct-professor of Medicine at McGill University.

Bacteria bank has a unique collection of over 10,000 frozen bacteria which can be used for many different purposes.

1. susceptibility testing of potentially promising anti-microbial

agents developed by biotech companies or researchers in

universities.

2. susceptibility testing of new antibiotics against specific and

emerging pathogens such as MRSA ( Methicillin resistant

Staphyloccocus aureus), VRE ( Vancomycin Resistant Enterococcus).

3. susceptibility testing against a wide array of Gram negative

agents ( E. coli, Salmonella, shigella, and other gastro-

intestinal pathogens responsible for million of deaths every year

in the world)

4. susceptibility testing of new agents against Streptococcus

pneumoniae responsible for the majority of sinusitis, otitis

media, pneumonia and some forms of bronchitis. In North America

only, there are over 300 million of antibiotic prescriptions in

the outpatients setting, and S.pneumonie is the number one target

overall by far.

5. bacteria useful for the development of newly designed genetically

derived products ( human and animal hormones, growth factors,

cytokines...)

6. bacteria useful for teaching purposes ( Pharmaceutical companies,

universities and medical schools)

Speaking from the corporate head office in Montreal, Garth McIntosh, President &CEO of ICBS said, " This acquisition will further strengthen our position in the Bio medical industry". ICBS also owns 100% of Canadian Bio Med Systems Ltd. McIntosh further stated " I want to thank all of our shareholders that have supported us in the past year, we are working very hard to make this a profitable year for all. Thank you all for your encouragement and support".

You can visit them at: http://www.bacteriabank.com

This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of any number of factors, including the risk factors contained in the Company's disclosure documents.


'/>"/>
SOURCE INTER CANADIAN BUSINESS SERVICE
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Fiserv acquires crime management software firm
2. GenTel acquires GlaxoSmithKline chip platform
3. Tushaus Computer acquires managed service business
4. RedPrairie acquires Denver software company
5. Eagle Technology acquires some synergy
6. Brady Corp. acquires Korean counterpart
7. Canadian firm acquires Silicon Logic
8. Imago acquires synergistic British firm
9. Fiserv acquires insurance, training product lines
10. Amazon acquires Madison-based Shopbop
11. Metavante acquires health-care payments firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A ... offer a new way to treat the disease. Surviving Mesothelioma has just posted an ... Scientists from several Korean institutions based their mesothelioma study on the fact the Manumycin ...
(Date:5/19/2016)... , ... May 19, 2016 , ... Anton Paar USA, ... square foot office building is complete. The new structure adds a third office building ... Anton Paar USA purchased 2.4 acres of land, along with office space adjacent ...
(Date:5/19/2016)... NEW YORK , May 19, 2016 ... Biotech space will fully recover given the relentless pressures ... is for sure in the investors circle though - ... requires due-diligence. Ahead of today,s session, ActiveWallSt.com,s presents four ... PTLA ), Vitae Pharmaceuticals Inc. (NASDAQ: ...
(Date:5/19/2016)... , May 19, 2016 ... and (OTC PINK: RGBPP) announced today initiation of ... first cord blood based cancer immunotherapeutic product leveraging ... application, Regen described a generation of cord blood ... by gene silencing.  The product in development will ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):